Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The problem of uncontrolled hypertension

Abstract

It is well established that there is a continuous relationship between raised blood pressure and the risk of cardiovascular or cerebrovascular disease. Both systolic and diastolic hypertension are associated with increased risk, but systolic blood pressure appears to be a more important determinant of risk than diastolic blood pressure. Randomised controlled trials have clearly shown that lowering blood pressure results in significant reductions in cardiovascular mortality and morbidity, and hence current hypertension management guidelines recommend target blood pressures of below 140/90 mm Hg (135/85 mm Hg in the case of the WHO/ISH guidelines). Despite the clear evidence for the benefits of antihypertensive therapy, however, blood pressure is often not adequately controlled in clinical practice. Population surveys indicate that the proportion of patients achieving even conservative blood pressure targets may be only 20% or lower. A number of factors contribute to poor control of hypertension, including a focus by the physician on diastolic blood pressure, rather than the prognostically more important systolic pressure, and poor adherence to therapy by patients. Poor adherence may be largely attributable to adverse events, and there is evidence that the excellent tolerability profile of angiotensin II type 1 (AT1)-receptor blockers may help to increase the proportion of patients remaining on therapy. AT1-receptor blockers could thus make a potentially important contribution to solving the problem of uncontrolled hypertension.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. MacMahon S et al. Blood pressure, stroke and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias Lancet 1990 335: 765–774

    Article  CAS  PubMed  Google Scholar 

  2. Collins R et al. Blood pressure, stroke and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context Lancet 1990 335: 827–838

    Article  CAS  PubMed  Google Scholar 

  3. Guidelines Subcommittee. 1999 World Health Organization – International Society of Hypertension. Guidelines for the management of hypertension J Hypertens 1999 17: 151–183

  4. Stamler J, Stamler R, Neaton JD . Blood pressure, systolic and diastolic, and cardiovascular risks. US population data Arch Intern Med 1993 153: 598–615

    Article  CAS  PubMed  Google Scholar 

  5. Staessen JA et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials Lancet 2000 355: 865–872

    Article  CAS  PubMed  Google Scholar 

  6. Du X et al. Case-control study of stroke and the quality of hypertension control in north west England Br Med J 1997 314: 272–276

    Article  CAS  Google Scholar 

  7. MacMahon S, Rodgers A . The effects of antihypertensive treatment on vascular disease: reappraisal of the evidence in 1994 J Vasc Biol Med 1993 4: 265–271

    Google Scholar 

  8. Isles CG et al. Mortality inpatients of the Glasgow Blood Pressure Clinic J Hypertens 1986 4: 141–156

    Article  CAS  PubMed  Google Scholar 

  9. Hansson L et al. Randomised trial of old and new antihypertensive drugs in elderlypatients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study Lancet 1999 354: 1751–1756

    Article  CAS  PubMed  Google Scholar 

  10. Dahlöf B et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) Lancet 1991 338: 1281–1285

    Article  PubMed  Google Scholar 

  11. Lindholm LH et al. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial Lancet 2001 358: 539–544

    Article  CAS  PubMed  Google Scholar 

  12. Pahor M et al. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996 9: 695–699

    Article  CAS  PubMed  Google Scholar 

  13. Pahor M et al. Calcium-channel blockade and incidence of cancer in aged populations Lancet 1996 348: 493–497

    Article  CAS  PubMed  Google Scholar 

  14. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 Br Med J 1998 317: 703–713

  15. Mancia G, Grassi G . Rationale for the use of a fixed combination in the treatment of hypertension Eur Heart J 1999 1 (Suppl L): L14–L19

    Google Scholar 

  16. Primatesta P, Brookes M, Poulter NR . Improved hypertension management and control. Results form the Health Survey for England 1998 Hypertension 2001 38: 827–832

    Article  CAS  PubMed  Google Scholar 

  17. Perry HM Jr et al. Antihypertensive efficacy of treatment regimens used in Veterans Administration hypertension clinics. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents Hypertension 1998 31: 771–779

    Article  CAS  PubMed  Google Scholar 

  18. Swales JD . Current clinical practice in hypertension: the EISBERG (Evaluation and Interventions for Systolic Blood pressure Elevation – Regional and Global) project Am Heart J 1999 138: S231–S237

    Article  Google Scholar 

  19. Joint National Committee. Sixth National Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI) Arch Intern Med 1997 157: 2413–2446

  20. Hansson L et al. Effects of intensive blood-pressure lowering and low-dose aspirin inpatients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial Lancet 1998 351: 1755–1762

    Article  CAS  PubMed  Google Scholar 

  21. Jones JK et al. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population Br Med J 1995 311: 293–295

    Article  CAS  Google Scholar 

  22. Hosie J, Wiklund I . Managing hypertension in general practice: can we do better? J Hum Hypertens 1995 9 (Suppl 2): S15–S18

    Google Scholar 

  23. Bloom BS . Continuation of initial antihypertensive medication after one year of therapy Clin Ther 1998 20: 671–681

    Article  CAS  PubMed  Google Scholar 

  24. Chaput AJ . Persistency with angiotensin receptor blockers (ARB) versus other antihypertensives (AHT) using the Saskatchewan database Can J Cardiol 2000 16 (Suppl F): 194F (abstract 390)

    Google Scholar 

  25. Elmfeldt D, George M, Hübner R, Olofsson B . Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect J Hum Hypertens 1997 11 (Suppl 2): S49–S53

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to L H Lindholm.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lindholm, L. The problem of uncontrolled hypertension. J Hum Hypertens 16 (Suppl 3), S3–S8 (2002). https://doi.org/10.1038/sj.jhh.1001433

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001433

Keywords

This article is cited by

Search

Quick links